The pharmacokinetic profiles of SSRIs: Clinical relevance

Primary Care Psychiatry

Volumn 5, Issue 2, 1999, Pages 65-69

  Kasper, Siegfried ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressant; Depression; Half life; Metabolite; Pharmacokinetics; SSRI

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DRUG HALF LIFE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032874338     PISSN: 13552570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Lépine J-P, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in Europe and Society). Int Clin Psychopharmacol 1997; 12:19-29.
2. Lecrubier Y. Impact of comorbidity on the treatment of panic disorder. J Clin Psychiatr 1998; 59 (Suppl 8):11-14.
3. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharmacol 1992; 11:930-957.
4. Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, et al. Double-blind study of the efficacy of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8:197-202
5. Holliday SM, Plosker GL. Paroxetine: a review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging 1993; 3:278-299.
6. Gram LF. Fluoxetine. New Engl J Med 1994; 331:1354-1361.
7. Stokes PE, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19:1135-1250.
8. British Medical Association and Royal Pharmaceutical Society of Great Britain. Antidepressant drugs. In British National Formulary March 1998. London. pp.176-186. Pharmaceutical Press, 1998.
9. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiat 1998, 155 (Suppl): 1-34.
10. Judge R, Steiner M. The long term efficacy and safety of paroxetine in panic disorder. Eur Neuropsychopharmacol 1996; 6(3 suppl):207.
11. Lecrubier Y, Bakker A, Dunbar G, Judge R. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiat Scand 1997; 95:145-152.
12. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiat Scand 1997; 95:153-160.
13. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiat 1995 167:374-379,
14. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiat 1998; 59 (Suppl 8):47-54,
15. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiat 1994; 51:559-567.
16. Piggott TA, Seay S. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiat 1999; 60(2):101-106.
17. Davidson JRT, Pharmacotherapy of social anxiety disorder. J Clin Psychiat 1998; 59 (Suppl 17):47-51.
18. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalised social phobia (social anxiety disorder): a randomised, controlled trial. J Am Med Assoc 1998, 280:708-713.
19. Baldwin D, Bobes J, Stein DJ, Scharwächter I, Faure M. A randomised, double-blind, placebo-controlled study of paroxetine in the treatment of social phobia/social anxiety disorder. Br J Psychiat in press.
20. Luo H, Richardson JS. A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. Int J Clin Psychopharmacol 1993. 8:3-12.
21. Milne RJ, Goa KL. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41:450-477.
22. Kragh-Sørensen P, Overø KF, Petersen OL, Jensen K, Parnas W. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol 1981; 48:53-60.
23. Overø KF. Preliminary studies of the kinetics of citalopram in man. Eur J Clin Pharmacol 1978; 14:69-73.
24. Frampton M. Citalopram: a review of pharmacology and clinical efficacy. J Serotonin Res. 1997, 4:29-45.
25. Bergstrom RF, Lemberger L, Farid NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiat 1988; 153 (Suppl 3): 47-50.
26. Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32:481-508.
27. Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32:313-334.
28. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, et al. A review of the metabolism and pharmacokinetic s of paroxetine in man. Acta Psychiat Scand 1989. 80 (Suppl 350):60-75.
29. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiat 1988; 49 (Suppl):46-51,
30. DeVane CL. Pharmacokinetic s of the newer antidepressants: clinical relevance Am J Med 1994, 97 (Suppl 6A): 13S-23S,
31. Preskorn S. Pharmacokinetics of antidepressants : why and how they are relevant to treatment. J Clin Psychiat 1993; 54 (Suppl): 14-34.
32. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994; 9 (Suppl 3): 13-19.
33. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. Human brain fluoxetine concentrations. J Neuropsychiats 1993; 5:322-329.
34. Renshaw PE Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiat 1992, 149:1592-1594,
35. Pato ME Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psycopharmacol 1991; 11:224-225.
36. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain, Neuropsychopharmacology 1993; 8:337-344.
37. Johnson AM. The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In Perspectives in Psychiatry Volume 1: Selective Serotonin Re-uptake Inhibitors. Feighner JP, Boyer WF (editors). Chichester: John Wiley & Sons: 1991
38. Hyttel J. Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5-HT uptake in rat brain synaptosomes in vitro Psychopharmacology (Berl) 1978: 60:13-18.
39. Crewe HK. Lermard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes BrJ Clin Pharmacol 1992; 34:262-265.
40. Nemeroff CB, De Vane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiat 1996, 153:311-320.
41. Greenblatt DJ, Von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiat 1998; 59 (Suppl 15):19-27.
42. Jefferson JW. Drug interactions - friend or foe ? J Clin Psychiat 1998; 59 (Suppl 4):37-47.
43. Preskorn S. Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes, J Psychopharmacol 1998; 12 (Suppl B): S89-97.
44. Richelson E. Pharmacokinetic interactions of antidepressants. J Clin Psychiat 1998; 59 (Suppl 10):22-26.
45. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-Tricyclic antidepressant interaction. An accidental finding, Eur J Clin Pharmacol 1991; 40:119-120.
46. Westermeyer J. Fluoxetine-induced tricyclic toxicity: extent and duration. J Clin Pharmacol 1991; 31:388-392.
47. Barros J, Asnis G. An interaction of sertraline and desipramine. Am J Psychiat 1993; 150:1751.
48. Lydiard RB, Anto RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiat 1993; 150:1125-1126.
49. Sindrup SH, Brøsen K, Hansen MGJ Aaes-Jørgensen, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monitor 1993, 15:11-17.
50. Lepola U, Leinonen E, Koponen H. Increased serum drug concentrations in concomitant treatment with citalopram, clomipramine and alprazolam. Eur Psychiat 1994, 9:312-314,
51. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine Eur J Clin Pharmacol 1993; 44:349-355.
52. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50:10-15.
53. Fritzel J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiat Scand 1991; 84:583-584,
54. Andersen BB, Mikkelsen M, Vesterager A, Dam M, Kristensen HB, Pedersen B, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991; 10:201-204.
55. Bannister SJ, Houser VP. Hulse JD, Kisicki JC, Rasmussen JGC. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiat Scand 1989, 80 (Suppl 350):102-106.
56. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, et al, Selective serotonin re-uptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39:151-159.
57. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 1991. 6:460-462.
58. Council of the Royal Pharmaceutical Society of Great Britain 1993. In Martindale. The Extra Pharmacopoeia Reynolds JEF (editor). London: The Pharmaceutical Press, 1993.
59. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psycopharmacol 1996, 16:356-362.
60. Haddad F. Newer antidepressants and the discontinuation syndrome. J Clin Psychiat 1997; 58(Suppl 7):17-22.
61. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeaux M, Rosenbaum JF, Young AH, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiat 1997, 58(Suppl 7):5-10.
62. Haddad P, Lejoyeux M, Young A. Antidepressant discontinuation reactions. Br Med J 1998; 316:1105-1106.